Nanomedicine in the Management of Alzheimer’s Disease: State-of-the-Art

Alzheimer’s disease (AD) is a deadly, progressive, and irreversible brain condition that impairs cognitive abilities. Globally, it affects 32.6 million individuals, and if no viable therapies are available by 2050, that figure might rise to 139 million. The current course of treatment enhances cogni...

Descripción completa

Detalles Bibliográficos
Autores principales: Mir Najib Ullah, Shehla Nasar, Afzal, Obaid, Altamimi, Abdulmalik Saleh Alfawaz, Ather, Hissana, Sultana, Shaheen, Almalki, Waleed H., Bharti, Pragya, Sahoo, Ankit, Dwivedi, Khusbu, Khan, Gyas, Sultana, Shahnaz, Alzahrani, Abdulaziz, Rahman, Mahfoozur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296528/
https://www.ncbi.nlm.nih.gov/pubmed/37371847
http://dx.doi.org/10.3390/biomedicines11061752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296528/
https://www.ncbi.nlm.nih.gov/pubmed/37371847
http://dx.doi.org/10.3390/biomedicines11061752

Ejemplares similares